NTLA · Intellia Therapeutics, Inc.

This bylaw amendment reflects a targeted governance update rather than a strategic or financial inflection point. The two principal changes — the cure provision for shareholder notices and the federal forum designation — are procedural enhancements common among U.S. public companies seeking to balance shareholder rights with board oversight efficiency. The cure mechanism mitigates the risk that minor, correctable errors in notice submissions (e.g., incomplete disclosures or formatting issues) would result in automatic exclusion of nominations or proposals, thereby supporting more robust shareholder engagement. The federal forum clause aligns with precedent set by Delaware Chancery Court rulings permitting such provisions for federal securities claims, aiming to consolidate related litigation and reduce duplicative proceedings across jurisdictions. Neither change alters the Company’s capital structure, operations, executive leadership, or financial obligations. As no financial metrics, executive transitions, material agreements, or voting outcomes are disclosed, the impact is confined to corporate governance mechanics and does not signal operational developments or regulatory exposure beyond standard securities litigation risk allocation.